Ellul-Micallef R
Eur J Respir Dis Suppl. 1982;122:118-25.
Corticosteroids have now been used in the treatment of bronchial asthma for about 30 years but objective physiological evidence of their effects in this condition has only become available over the past 8 years. Studies with oral prednisolone, intravenous prednisolone and hydrocortisone, as well as with inhaled budesonide, in patients with chronic bronchial asthma, have shown that there is a time lag between the administration of these drugs and the onset of improvement in the patients' conditions. This time lag is even longer when corticosteroids are given to patients with severe asthma. It appears that these drugs exert an effect on both the central and the peripheral airways. Unlike bronchodilators corticosteroids do not appear to increase the degree of ventilation perfusion mismatching present in asthma. They have been shown to decrease the alveolar-arterial oxygen tension gradient and the venous admixture effect with a consequent rise in arterial oxygen tension. It is still uncertain how corticosteroids work in asthma; it seems, however, that one of the ways may be through their effects on the beta adrenergic receptors.
皮质类固醇用于治疗支气管哮喘已有约30年,但有关其在这种疾病中作用的客观生理学证据仅在过去8年才获得。对慢性支气管哮喘患者使用口服泼尼松龙、静脉注射泼尼松龙和氢化可的松以及吸入布地奈德的研究表明,这些药物的给药与患者病情改善之间存在时间滞后。当给重度哮喘患者使用皮质类固醇时,这种时间滞后甚至更长。这些药物似乎对中央气道和外周气道都有作用。与支气管扩张剂不同,皮质类固醇似乎不会增加哮喘中存在的通气灌注不匹配程度。它们已被证明可降低肺泡-动脉氧分压差和静脉混合效应,从而使动脉氧分压升高。皮质类固醇在哮喘中如何发挥作用仍不确定;然而,似乎其中一种方式可能是通过它们对β肾上腺素能受体的作用。